Campbell Murray
Managing Director
Gordon Winston joined DRI Capital as Executive Vice President, Finance in September of 2002. Prior to this appointment, Gordon Winston served as a consultant to Wesbild Capital Corporation, Inc., a subsidiary of Inwest Investments Ltd. In this capacity he was responsible for evaluating private and public market investment opportunities and managed a $25 million portfolio. Gordon has held a number of senior positions with Wall Street investment banks and with boutique merchant banks. These include Lehman Brothers, Kidder, Peabody & Company, and Hamilton Capital Group Ltd., where Gordon contributed to key finance agreements with life sciences companies. Gordon received his Bachelor of Sciences in Economics from Fordham University.
Mark Carthy, Managing Partner Orion Healthcare Equity Partners
Mark Carthy co-founded Orion Healthcare Equity Partners in 2007. Mark Carthy has 22 years of operating and investment experience in healthcare companies. Mark Carthy joined Oxford in 2000 and became General Partner in 2001. At Oxford, Mark Carthy was responsible for 13 investments totaling $117 million in committed capital. Before joining Oxford, he was Biotechnology Portfolio Manager at Morningside Ventures where he focused on early stage private equity investments. Previously, he was Chief Business Officer of Cubist Pharmaceuticals, where he in-licensed Cubicin, Cubist's commercial antibiotic which reached annual sales of $414.7 million in 2008. Mark Carthy was also Senior Director of Business Development at Vertex Pharmaceuticals. He received his B.E. in Chemical Engineering from University College Dublin, Ireland and an M.S. in Chemical Engineering from University of Missouri. He received his MBA from Harvard Business School in 1987. Mark Carthy was recently listed on the Forbes 2009 Midas List as one of the leading venture capitalists.
About Kenneth Greenberg, MD " Principal -- MPM Capital
Dr. Kenneth Greenberg joined MPM Capital from McKinsey & Co., where he worked on R&D and corporate strategy for life science companies, and on buyout transactions for private equity clients. Prior to joining McKinsey, Dr. Kenneth Greenberg advised biotechnology and medical device companies as an investment banker at Merrill Lynch. He also worked at Health Market, a health insurance company, where he oversaw disease management programs. Dr. Kenneth Greenberg earned his M.D. at the University of Pennsylvania, graduating with AOA honors, and subsequently trained as an ophthalmology resident at Johns Hopkins. He holds an M.B.A. from the Wharton School and a B.A. in Economics from Duke University, where he graduated Phi Beta Kappa.
About Dr. Campbell Murray, Managing Director -- Novartis Venture funds in Cambridge, MA, USA.
Prior to joining the venture fund in 2005, he worked at the Novartis Institutes for BioMedical Research as the director of special projects reporting to the president & CEO. Campbell Murray, is a New Zealand trained physician, Kauffman Fellow and holds an MBA from Harvard Business School and an MPP (public policy) from the John F. Kennedy School of Government where he was a Knox Fellow and Rotary Ambassadorial Scholar. Campbell Murray serves as a director on the boards of Aileron Therapeutics, Akebia Therapeutics, Alios BioPharm, BioRelix, and ProCertus BioPharm and as an observer on the board of MicroCHIPS and Tepha.